You're not just taking drops
Discuss individual risk tolerance and priorities with your doctor when retatrutide becomes available
Mounjaro patients histories are a bit of a mix: 56% of patients have evidence of a diabetes treatment before starting Mounjaro, but 39% are nave to any prior diabetes pharmaceutical
GLP-1 also decreases the glucose production from the liver 1
The honeymoon may capture headlines, but durability, safety, and access will define the future of GLP-1 and metabolic therapies
This blog explores the science behind GLP-1 plateaus , why they occur, and what providers can do to prevent, reverse, or bypass them through smart cycling strategies, metabolic support, and adjunctive protocols like SLM+